Literature DB >> 1327403

Effects of repeated administration of desipramine or electroconvulsive shock on norepinephrine uptake sites measured by [3H]nisoxetine autoradiography.

M E Bauer1, S M Tejani-Butt.   

Abstract

To determine if repeated administration of desipramine (DMI) or electroconvulsive shock (ECS) regulate uptake sites for norepinephrine (NE) in rat brain, the binding of [3H]nisoxetine ([3H]NIS) was measured using quantitative autoradiography. Groups of animals were given DMI intraperitoneally, either a single injection or repeated doses of 10 mg/kg once daily for 21 days and were killed 48 h after the last injection. Another group of rats received ECS daily for 12 days (150 mA, 300 ms, 60 Hz) and was killed 24 h after the last shock. Repeated administration of DMI caused statistically significant decreases (20-40%) in the binding of [3H]NIS in 8 out of 17 brain regions measured; these areas included the hippocampus, thalamus and the amygdala. Acute treatment with DMI had no effect on the binding of [3H]NIS in any of the regions analyzed except the centrolateral nucleus of the amygdala. By contrast, except for the paraventricular nucleus of the thalamus where ECS caused a modest (20%) increase in binding, no other brain region was affected by ECS. Thus it appears that repeated administration of DMI and chronic ECS treatment have different effects on the binding of [3H]NIS to uptake sites for NE in rat brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327403     DOI: 10.1016/0006-8993(92)90134-u

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

2.  Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei.

Authors:  G A Ordway; C A Stockmeier; G W Cason; V Klimek
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

3.  Chronic desipramine treatment alters tyrosine hydroxylase but not norepinephrine transporter immunoreactivity in norepinephrine axons in the rat prefrontal cortex.

Authors:  Susan L Erickson; Anjalika R Gandhi; Josephine K Asafu-Adjei; Allan R Sampson; LeeAnn Miner; Randy D Blakely; Susan R Sesack
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-06       Impact factor: 5.176

4.  Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies.

Authors:  Megan E Kozisek; Jean D Deupree; William J Burke; David B Bylund
Journal:  J Neurosci Methods       Date:  2007-02-22       Impact factor: 2.390

5.  Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.

Authors:  Pamela J McMillan; Sylvia S White; Allyn Franklin; J Lynne Greenup; James B Leverenz; Murray A Raskind; Patricia Szot
Journal:  Brain Res       Date:  2010-12-11       Impact factor: 3.252

6.  Reduced levels of norepinephrine transporters in the locus coeruleus in major depression.

Authors:  V Klimek; C Stockmeier; J Overholser; H Y Meltzer; S Kalka; G Dilley; G A Ordway
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

7.  The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.

Authors:  Meng-Yang Zhu; Patrick B Kyle; Arthur S Hume; Gregory A Ordway
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

8.  Chronic oral nicotine increases brain [3H]epibatidine binding and responsiveness to antidepressant drugs, but not nicotine, in the mouse forced swim test.

Authors:  Jesper T Andreasen; Elsebet O Nielsen; John P Redrobe
Journal:  Psychopharmacology (Berl)       Date:  2009-05-12       Impact factor: 4.530

9.  Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3).

Authors:  John J Mooney; Jacqueline A Samson; John Hennen; Kathleen Pappalardo; Nancy McHale; Jonathan Alpert; Martha Koutsos; Joseph J Schildkraut
Journal:  J Psychiatr Res       Date:  2007-08-28       Impact factor: 4.791

10.  Desipramine induced changes in the norepinephrine transporter, alpha- and gamma-synuclein in the hippocampus, amygdala and striatum.

Authors:  Alexis M Jeannotte; John G McCarthy; Anita Sidhu
Journal:  Neurosci Lett       Date:  2009-10-08       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.